Edwards Lifesciences Co. (NYSE:EW) Position Raised by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. boosted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,615,163 shares of the medical research company's stock after acquiring an additional 921,500 shares during the quarter. Edwards Lifesciences accounts for 1.2% of Jacobs Levy Equity Management Inc.'s investment portfolio, making the stock its 11th biggest position. Jacobs Levy Equity Management Inc. owned 0.78% of Edwards Lifesciences worth $341,661,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $30,000. Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares of the company's stock, valued at $1,569,414.24. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,681 shares of company stock worth $6,492,703. Company insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. StockNews.com raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Morgan Stanley lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Robert W. Baird lifted their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $79.60.

Edwards Lifesciences Stock Performance

EW stock traded up $1.54 during midday trading on Wednesday, reaching $77.04. The company had a trading volume of 7,639,706 shares, compared to its average volume of 5,072,833. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $71.73 and a 200 day moving average price of $71.62. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The firm has a market capitalization of $45.19 billion, a PE ratio of 11.05, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.66 earnings per share. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.